PURPOSE: The epidermal growth factor receptor inhibitors, gefitinib and erlotinib, are used
as standard salvage therapy for advanced non-small-cell lung cancer (NSCLC). The aim of …

Non-small-cell lung cancer (NSCLC) remains the leading cause of cancer-related death in
both men and women in the United States. Platinum-based doublet chemotherapy has been …

Brain metastases (BM) are a common occurrence in patients with non-small cell lung cancer
(NSCLC). Standard therapy options include whole brain radiotherapy and, in selected …

Small interfering RNA (siRNA) provides a promising therapeutic approach in the silencing of
disease‑causing genes. In the present study, the use of 2'‑O‑methyl‑modified siRNA‑cluster …

Objective: Due to the initiation of the priority review program in China, many antitumor drugs
have been approved for marketing based on phase II clinical trials and short-term surrogate …

Longitudinal studies have been conducted in various fields, including medicine, economics
and the social sciences. In this paper, we focus on longitudinal ordinal data. Since the …

We performed a meta-analysis of diarrhea and stomatitis associated with erlotinib use in
patients with advanced non-small cell lung cancer. Eligible studies included randomized …

目的比较厄洛替尼与吉非替尼治疗非小细胞肺癌(NSCLC) 脑转移的临床疗效.
方法回顾性分析2008 年3 月至2014 年3 月收治的73 例NSCLC 患者的临床资料 …

Adanya identifikasi Epidermal Growth Factor Receptor (EGFR) sebagai target molekular
mempengaruhi model terapi kanker paru jenis Non-Small Cell Lung Cancer (NSCLC) …

The AURA1 trial included five patients with EGFR mutation other than exon 19 deletion or
exon 21 L858R point mutation, almost all of which were what we would call uncommon …